4-(4-hydroxy-3-chlorophenyl)-tetrahydropyran | 62071-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-(4-hydroxy-3-chlorophenyl)-tetrahydropyran
• 英文别名: 2-Chloro-4-(4-tetrahydropyranyl)phenol；2-Chloro-4-(oxan-4-yl)phenol
• CAS: 62071-42-5
• 化学式: C₁₁H₁₃ClO₂
• 分子量: 212.676
• InChiKey: CFUJELSQEDCPFP-UHFFFAOYSA-N

物化性质

• 沸点：
  323.8±42.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-hydroxy-3-chlorophenyl)-tetrahydropyran 在 sodium hydroxide 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 12.0h， 生成 (2R)-7-(3-(2-Chloro-4-(4-tetrahydropyranyl)phenoxy)propoxy)-2-ethylchromane-2-carboxylic acid
  参考文献：
  名称：

  (2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

  摘要：

  A SAR study was conducted on chromane-2-carboxylic acid toward selective PPAR alpha agonisim. As a result, highly potent, and selective PPAR alpha agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.028
• 作为产物：
  描述：

  4-苄氧基溴苯 在 palladium on activated charcoal 盐酸 、 二异丁胺 、 磺酰氯 、 氢气 、 magnesium 作用下， 以 甲醇 为溶剂， 生成 4-(4-hydroxy-3-chlorophenyl)-tetrahydropyran
  参考文献：
  名称：

  (2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

  摘要：

  A SAR study was conducted on chromane-2-carboxylic acid toward selective PPAR alpha agonisim. As a result, highly potent, and selective PPAR alpha agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.028

文献信息

• Arylthiazolidinedione derivatives
  申请人：Merck & Co., Inc.

  公开号：US20020037911A1

  公开（公告）日：2002-03-28

  Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr; and/or &ggr; mediated diseases, disorders and conditions.

  取代5-芳基-2,4-噻唑烷二酮和噁唑烷二酮是PPAR的有效激动剂，因此在治疗、控制或预防糖尿病、高血糖、高脂血症（包括高胆固醇血症和高甘油三酯血症）、动脉粥样硬化、肥胖、血管再狭窄和其他PPARα和/或γ介导的疾病、疾病和情况中非常有用。
• Novel p-(4-tetrahydropyranyl)-phenoxy-compounds
  申请人：Roussel UCLAF

  公开号：US04078076A1

  公开（公告）日：1978-03-07

  Novel pyranic derivatives of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and cations of alkali metals, alkaline earth metals, aluminum, amines and ammonium R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms and X is selected from the group consisting of hydrogen, chlorine and bromine having hypolipemic activity and reducing the level of total lipids in plasma.

  新型吡喃衍生物的化学式为##STR1##其中R从氢、1至6个碳原子的烷基和碱金属、碱土金属、铝、胺和铵的阳离子中选择，R.sub.1和R.sub.2分别从氢和1至4个碳原子的烷基中选择，X从氢、氯和溴中选择，具有降血脂活性并减少血浆总脂类水平。
• Arylthiazolidinedione and aryloxazolidinedione derivatives
  申请人：Merck & Co. Inc.

  公开号：US06380191B1

  公开（公告）日：2002-04-30

  Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr; and/or &ggr; mediated diseases, disorders and conditions.

  5-芳基-2,4-噻唑烷二酮和噁唑烷二酮的替代物是PPAR的有效激动剂，因此在糖尿病、高血糖、高脂血症（包括高胆固醇血症和高甘油三酯血症）、动脉硬化、肥胖症、血管再狭窄和其他PPARα和/或γ介导的疾病、紊乱和病状的治疗、控制或预防中是有用的。
• ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES
  申请人：Merck & Co., Inc.

  公开号：EP1194147A1

  公开（公告）日：2002-04-10
• EP1194147A4
  申请人：——

  公开号：EP1194147A4

  公开（公告）日：2002-10-09